6 unknown, 3 recruiting, 2 not yet recruiting, 1 active not recruiting. 4 Phase 4, 3 Not applicable, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Unknown 3, Recruiting 1 |
| Not applicable | 3 | Not yet recruiting 2, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Institut fuer Frauengesundheit: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IMPLEMENTING PATIENTS' COMPETENCE IN ORAL EBC THERAPY PERSISTENCE Standardized patient coaching - HR+/HER2- Early Breast Cancer | Not applicable | Not yet recruiting | Institut fuer Frauengesundheit | 257 | 2026-10-01 | 2026-09-10 |
| ESR1Real World Assessment Prevalence Study ESR1 testing - HR+/HER2- aBC Undergoing 1L Treatment With CDK4/6i (Palbociclib, Abemaciclib or Ribociclib) and AI (Anastrozole or Letrozole) | Not applicable | Not yet recruiting | Institut fuer Frauengesundheit | 1550 | 2026-10-01 | 2026-09-14 |
| Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer HR+/HER2- Early Breast Cancer | Recruiting | Institut fuer Frauengesundheit | 200 | 2026-02-19 | 2026-05-14 | |
| Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management Typology-based coaching - HR+/HER2- Early Breast Cancer | Not applicable | Recruiting | Institut fuer Frauengesundheit | 548 | 2025-11-04 | 2026-07-16 |
| CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer Breast Cancer, HER2-negative Breast Cancer | Unknown | Institut fuer Frauengesundheit | 3000 | 2023-03-10 | 2023-05-23 | |
| Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients Ribociclib - Breast Cancer, Breast Neoplasms | Phase 4 | Recruiting | Institut fuer Frauengesundheit | 1000 | 2022-10-12 | 2023-04-18 |
| Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO Pembrolizumab Injection [Keytruda], Olaparib Oral Tablet [Lynparza] - Malignant Neoplasm of Breast, Breast Cancer | Phase 2 | Active not recruiting | Institut fuer Frauengesundheit | 11 | 2022-07-30 | 2024-05-07 |
| Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) Ontruzant, Chemotherapy, Pertuzumab - Breast Cancer, Breast Neoplasms | Phase 4 | Unknown | Institut fuer Frauengesundheit | 108 | 2021-07-11 | 2023-04-18 |
| Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer Eribulin Injection [Halaven], Paclitaxel injection - Breast Cancer Female, Neoplasm, Breast | Phase 4 | Unknown | Institut fuer Frauengesundheit | 82 | 2021-03-11 | 2023-04-18 |
| Implementing Patients´ Competence in Oral Breast Cancer Therapy Metastatic Breast Cancer, Advanced Breast Cancer | Unknown | Onco Medical Consult GmbH | 212 | 2020-03-01 | 2020-02-05 | |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC Pembrolizumab, nab-paclitaxel, Epirubicin - Malignant Neoplasm of Breast | Phase 2 | Completed | Institut fuer Frauengesundheit | 53 | 2018-03-23 | 2021-04-08 |
| Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) Letrozole - is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients. | Phase 4 | Unknown | Institut fuer Frauengesundheit | 3545 | 2009-02-01 | 2013-07-25 |
| Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma Paclitaxel, Cisplatin/Paclitaxel - Recurrent, Persistent or Metastasized Cervical Cancer | Phase 3 | Unknown | Institut fuer Frauengesundheit | 312 | 2006-09-01 | 2012-04-12 |
Breast Neoplasms (7) · Recurrence (1) · Triple Negative Breast Neoplasms (1)
Paclitaxel (3) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Cyclophosphamide (1) · Drug Therapy (1) · Epirubicin (1) · Letrozole (1) · Ontruzant (1) · TP protocol (1) · eribulin (1) · olaparib (1) · pertuzumab (1) · ribociclib (1)
Germany (12)
Andreas Schneeweiss, MD, Prof. (2) · Manfred Welslau, Dr. med. (2) · Peter A Fasching, MD, Prof. (2) · Peter A. Fasching, MD, Prof. (2) · Peter A. Fasching, Prof. Dr. med. (2) · Falk Thiel, Dr. med. (1) · Hans Tesch, Prof. Dr. med. (1) · Nina Ditsch, Prof. Dr. med. (1) · Peter Andreas Fasching, Prof. Dr. (1) · Tanja Fehm, MD, Prof. (1) · Tanja Fehm, Prof. Dr. (1)
2016 (1)